Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11419942 Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Patent 11419942 was granted and assigned to Alnylam Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Alnylam Pharmaceuticals

0

Current Assignee

Alnylam Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Brian Bettencourt0

Donald Foster0

Stuart Milstein0

Satyanarayana Kuchimanchi0

Martin A. Maier0

Klaus Charisse0

Gregory Hinkle0

Date of Patent

August 23, 2022

0

Patent Application Number

170209540

Date Filed

September 15, 2020

0

Patent Citations

US Patent 10238749 Angiotensinogen (AGT) iRNA compositions and methods of use thereof

US Patent 10709728 Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

Patent Citations Received

US Patent 11834661 Angiotensinogen (AGT) iRNA compositions and methods of use thereof

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11419942 Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool